By Fineline Cube 
On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) to commercialize onradivir tablets in Macau, China. This collaboration marks a significant step in the commercialization of this innovative antiviral medication.
About Onradivir
Onradivir is the world’s first influenza RNA polymerase PB2 protein inhibitor. It was independently developed by Guangdong Raynovent Biotech Co., Ltd., a subsidiary of Zhongsheng Pharmaceutical. The drug received marketing approval from China’s National Medical Products Administration (NMPA) in May 2025 for the treatment of uncomplicated influenza A in adults.
Commercialization Efforts
Through this partnership, Kexing Biopharm and Guangdong Zhongsheng aim to leverage their combined expertise to successfully introduce onradivir tablets to the Macau market. This initiative underscores their commitment to providing innovative treatment options for influenza patients.-Fineline Info & Tech